Compare
Vor Biopharma Inc. vs REGENXBIO Inc. vs Monte Rosa Therapeutics, Inc. vs Cullinan Therapeutics, Inc.
| Latest fiscal year | Vor Biopharma Inc. VOR | REGENXBIO Inc. RGNX | Monte Rosa Therapeutics, Inc. GLUE | Cullinan Therapeutics, Inc. CGEMRevenue covers only part of its income (partial revenue) |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $170.44M | $123.67M | n/a |
| Revenue growth (YoY) | n/a | +104.5% | +63.5% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -94.6% | -43.8% | n/a |
| Net margin | n/a | -113.8% | -31.2% | n/a |
| Net income | -$695.98M | -$193.88M | -$38.63M | -$219.88M |
| EPS (Diluted) | -$70.50 | -$3.76 | n/a | n/a |
| Operating cash flow | -$142.71M | -$123.96M | -$22.80M | -$175.75M |
| Free cash flow | -$143.65M | -$126.38M | -$27.50M | -$175.80M |
| Cash & equivalents | $396.49M | $34.47M | $129.88M | $88.33M |
| Total assets | $464.13M | $453.03M | $448.66M | $448.37M |
| Total liabilities | $628.44M | $350.30M | $215.60M | $39.64M |
| Shareholders' equity | -$164.31M | $102.73M | $233.06M | $408.73M |
| Return on year-end equity | n/a | -188.7% | -16.6% | -53.8% |
| Shares outstanding | 38.72M | 50.89M | 65.54M | 60.24M |
Revenue, most recent five fiscal years
| Fiscal year | Vor Biopharma Inc. | REGENXBIO Inc. | Monte Rosa Therapeutics, Inc. | Cullinan Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $170.44M Ended 2025-12-31 | $123.67M Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $83.33M Ended 2024-12-31 | $75.62M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $90.24M Ended 2023-12-31 | $0 Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $112.72M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $470.35M Ended 2021-12-31 | n/a | n/a |